Upstream Bio Q2 FY26 net loss narrows 0.66% to $39.7 million
UPB•Cash position and clinical program updates
Cash, cash equivalents and short-term investments totaled $261.3 million as of June 30, expected to fund operations through 2027.
Enrollment finished in the Phase 2 VENTURE COPD trial with 481 participants; data are expected in the second half of 2027.
Management reiterated plans to start Phase 3 trials of verekitug in severe asthma and CRSwNP in Q1 2027, with FDA End-of-Phase 2 interactions on track.
Quarterly loss narrows as expenses decline
Upstream Bio posted a net loss of $39.7 million, narrowing from $40 million a year earlier.
Research and development expense slipped 4.75% to $36.1 million, while general and administrative costs eased 4.04% to $7.1 million.
